Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SECOND QUARTER CONSOLIDATED REVENUES OF $2.85 BILLION, UP 13% ON A REPORTED BASIS AND 11% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET INCOME ATTRIBUTABLE TO BAUSCH HEALTH OF $258 MILLION AND GAAP NET INCOME OF $260 MILLION GAAP EARNINGS PER DILUTED SHARE ATTRIBUTABLE TO BAUSCH HEALTH OF $0.68 COMPARED TO $0.40 IN THE PRIOR YEAR PERIOD; ADJUSTED EARNINGS PER DILUTED SHARE (NON-GAAP)1 OF $1.26 COMPARED TO $0.90 IN THE PRIOR YEAR PERIOD, AN INCREASE OF 40% CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $1,075 MILLION, UP 28% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2026 RESULTS DELIVERED THIRTEENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE GROWTH, WITH REVENUE UP 16% ON A REPORTED BASIS AND 13% ON AN ORGANIC (NON-GAAP)1 BASIS NET INCOME INCREASED $84 MILLION OVER THE PRIOR YEAR PERIOD, AND ADJUSTED EBITDA (NON-GAAP)1 GREW 28% GENERATED $517 MILLION IN CASH PROVIDED BY OPERATING ACTIVITIES AND $471 MILLION IN ADJUSTED CASH FLOWS FROM OPERATIONS (NON-GAAP)1  RAISING FULL-YEAR 2026 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOWS FROM OPERATIONS (NON-GAAP)1 GUIDANCE LAVAL, QC, JULY 29, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "THE SECOND QUARTER MARKS OUR THIRTEENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH IN REVENUE AND ADJUSTED EBITDA FOR BAUSCH HEALTH, EXCLUDING BAUSCH + LOMB, REFLECTING THE STRENGTH OF OUR PORTFOLIO, DISCIPLINED EXECUTION, AND THE DEDICATION OF OUR TEAMS AROUND THE WORLD.

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

LAVAL, QC, JULY 7, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) WILL RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS AFTER MARKET CLOSE ON WEDNESDAY, JULY 29, 2026. BAUSCH HEALTH WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 5:00 P.M.

BAUSCH HEALTH TO ANNOUNCE SECOND QUARTER 2026 RESULTS ON JULY 29, 2026

LAVAL, QC, JULY 1, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT MICHAEL GOETTLER HAS RESIGNED FROM ITS BOARD OF DIRECTORS, EFFECTIVE JUNE 30, 2026, IN CONNECTION WITH HIS APPOINTMENT AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF KNOA PHARMA LLC. "WE THANK MICHAEL FOR HIS VALUED SERVICE AND WISH HIM THE BEST IN HIS NEW ROLE," SAID JOHN A.

MICHAEL GOETTLER RESIGNS FROM BAUSCH HEALTH'S BOARD OF DIRECTORS

THERMAGE  , A PIONEER IN NON-INVASIVE SKIN TIGHTENING, WAS AWARDED THE AAA WELL-KNOWN TRADEMARK CERTIFICATION, THE HIGHEST RECOGNITION IN CHINA'S DOMESTIC TRADEMARK EVALUATION SYSTEM. LAVAL, QC, MAY 28, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND SOLTA MEDICAL, A GLOBAL LEADER IN THE MEDICAL AESTHETICS MARKET, ARE PROUD TO ANNOUNCE THAT THEIR FLAGSHIP BRAND, THERMAGE, WAS AWARDED THE PRESTIGIOUS AAA WELL-KNOWN TRADEMARK CERTIFICATION ("AAA") BY THE CHINA TRADEMARK ASSOCIATION (CTA), A RENOWNED ACCREDITATION RESERVED FOR TOP-TIER BRANDS.

BAUSCH HEALTH'S AESTHETIC BUSINESS, SOLTA MEDICAL, EARNS PRESTIGIOUS TRADEMARK CERTIFICATION OF THERMAGE IN CHINA

LAVAL, QC, MAY 19, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT SHAREHOLDERS ELECTED ALL 10 DIRECTOR NOMINEES AT ITS 2026 ANNUAL MEETING OF SHAREHOLDERS ("ANNUAL MEETING") HELD ON MAY 19, 2026, INCLUDING EIRY W. ROBERTS, M.D.

BAUSCH HEALTH ANNOUNCES 2026 ANNUAL MEETING OF SHAREHOLDER RESULTS

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THE U.S. LAUNCH OF PRESERVISION AREDS3 EYE VITAMINS, WHICH COMBINE THE CLINICALLY PROVEN AREDS2 NUTRIENTS RECOMMENDED BY THE NEI TO HELP REDUCE THE RISK OF MODERATE-TO-ADVANCED AMD PROGRESSION WITH A UNIQUE B-VITAMIN COMPLEX.* BUILT ON DECADES OF LEADERSHIP IN AREDS-BASED VITAMINS, PRESERVISION AREDS3 IS THE MOS.

BAUSCH + LOMB LAUNCHES PRESERVISION AREDS3 EYE VITAMINS IN THE UNITED STATES

LAVAL, QC, MAY 13, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT THOMAS J. APPIO, CHIEF EXECUTIVE OFFICER, AND JEAN-JACQUES CHARHON, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE RBC CAPITAL MARKETS 2026 GLOBAL HEALTHCARE CONFERENCE IN NEW YORK CITY ON WEDNESDAY, MAY 20, 2026.

BAUSCH HEALTH TO PARTICIPATE IN RBC CAPITAL MARKETS 2026 GLOBAL HEALTHCARE CONFERENCE

LAVAL, QC, MAY 12, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT MEMBERS OF COMPANY MANAGEMENTWILL PARTICIPATE IN A FIRESIDE CHAT AT THE BARCLAYS 30TH ANNUAL LEVERAGED FINANCE CONFERENCE IN AUSTIN, TEXAS ON TUESDAY, MAY 19, 2026. A LIVE AUDIO WEBCAST OF THE EVENT WILL BE ACCESSIBLE ON THE INVESTOR RELATIONS SECTION OF BAUSCH HEALTH'S WEBSITE.

BAUSCH HEALTH TO PARTICIPATE IN BARCLAYS 30TH ANNUAL LEVERAGED FINANCE CONFERENCE

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THE EUROPEAN LAUNCH OF THE BI-BLADE+ ADVANCED DUAL-PORT VITRECTOMY CUTTER ON THE STELLARIS ELITE VISION ENHANCEMENT SYSTEM. THE LAUNCH OF BI-BLADE+ IS THE LATEST EXAMPLE OF OUR COMMITMENT TO DELIVERING MEANINGFUL INNOVATION IN EUROPE, SAID LUC BONNEFOY, PRESIDENT, SURGICAL, BAUSCH + LOMB. STELLARIS ELITE HAS.

BAUSCH + LOMB LAUNCHES BI-BLADE+ DUAL-PORT VITRECTOMY CUTTER IN EUROPE

FIRST QUARTER CONSOLIDATED REVENUES OF $2.52 BILLION, UP 12% ON A REPORTED BASIS AND 7% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET LOSS ATTRIBUTABLE TO BAUSCH HEALTH OF $1,423 MILLION AND GAAP NET LOSS OF $1,431 MILLION, INCLUSIVE OF A $1,426 MILLION GOODWILL IMPAIRMENT CHARGE GAAP LOSS PER SHARE OF ($3.82) (BASIC AND DILUTED) COMPARED TO ($0.16) IN THE PRIOR YEAR PERIOD ADJUSTED EARNINGS PER DILUTED SHARE (NON-GAAP) OF $0.78 COMPARED TO $0.59 IN THE PRIOR YEAR PERIOD, AN INCREASE OF 32% CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $837 MILLION, UP 27% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2026 RESULTS DELIVERED TWELFTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE GROWTH AND ADJUSTED EBITDA (NON-GAAP)1 GROWTH, WITH 14% REPORTED AND 9% ORGANIC (NON-GAAP)1 REVENUE GROWTH AND 17% ADJUSTED EBITDA (NON-GAAP)1 GROWTH GENERATED $319 MILLION IN ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP) 1 REAFFIRMING FULL-YEAR 2026 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP)1 GUIDANCE LAVAL, QC, APRIL 29, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "OUR FIRST QUARTER PERFORMANCE MARKS TWELVE CONSECUTIVE PERIODS OF YEAROVERYEAR GROWTH IN REVENUE, ADJUSTED EBITDA FOR BAUSCH HEALTH EXCLUDING BAUSCH + LOMB, REFLECTING STRATEGIC EXECUTION AND DISCIPLINED ACCOUNTABILITY ACROSS OUR ORGANIZATION.

Bausch Health Companies Inc.

BHC

Price

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHC